Insulet price target lowered to $338 from $345 at Citi

Citi lowered the firm’s price target on Insulet (PODD) to $338 from $345 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.